Table 2.
Reclassification by selected models of patients treated by antibiotics.
| Selected Models | Patients Who Received Antibiotics | |
|---|---|---|
| Patients from the Infected Group, Reclassified as Not Infected Using Biomarker Models (n/N, %) |
Patients from the Not Infected Group, Also Classified as Not Infected Using Biomarker Models (n/N, %) |
|
| IL-6 | 5/51 (9.8%) | 10/42 (23.8%) |
| IL-10 | 5/51 (9.8%) | 26/42 (61.9%) |
| NGAL | 5/49 (10.2%) | 25/42 (59.5%) |
| PCT/IL-10 | 5/51 (9.8%) | 26/42 (61.9%) |
| PTX3/NGAL | 5/49 (10.2%) | 27/42 (64.3%) |
| PTX3/NGAL/gelsolin | 5/49 (10.2%) | 23/41 (56.1%) |
| IL-6 | 5/51 (9.8%) | 10/42 (23.8%) |
Data represent the proportion of patients reclassified using the best selected models among patients treated by antibiotics (51 and 42 neonates classified by adjudication committee as patients with infected and not infected status, respectively). There is missing data for 3 biomarkers’ detection.